CDC42 and melanoma: These results suggest that WYC‐209 selectively targeted on TRC primarily via RARγ, consistent with the previous reports that RARγ acts as an oncogene in regulating cell fate in melanoma cells.[14, 15] Pretreating TRCs with the specific RARγ antagonist MM11253 delayed WYC‐209‐mediated Cdc42 downregulation (Figure 4A–D).